Wei Li1, Jun Han2, Guowei Xie1, Yang Xiao1, Ke Sun1, Kefei Yuan3, Hong Wu4. 1. Department of Liver Surgery and Liver Transplantation Centre, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. 2. Department of Critical Care Medicine, Sichuan Provincial Hospital for Women and Children, Chengdu, 610045, Sichuan, China. 3. Department of Liver Surgery and Liver Transplantation Centre, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. ykf13@163.com. 4. Department of Liver Surgery and Liver Transplantation Centre, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. wuhong7801@163.com.
Abstract
BACKGROUND: Although laparoscopic mesohepatectomy (LM) has been performed for patients with centrally located hepatocellular carcinoma (CL-HCC), its short- and long-term benefits compared with traditional open surgery remain unclear. The aim of the present study was to explore the independent role of LM in the prognosis of patients with CL-HCC. METHODS: A retrospective analysis was undertaken of 348 patients who underwent mesohepatectomy for CL-HCC between January 2012 and October 2017 in our hospital. The impact of the surgical methods on long-term prognosis was evaluated by multivariable regression analysis. In addition, patients in the LM group were matched in a 1:3 ratio with open mesohepatectomy (OM) group. RESULTS: Some 307 patients underwent OM and 41 had LM. In both adjusted and non-adjusted models, patients in LM group had similar overall survival (OS, both P > 0.05) and disease-free survival (DFS, both P > 0.05) compared to OM patients. The mean (s.d.) OS in LM and OM groups was 41.6 (7.2) and 46.4 (1.4) months, respectively. The mean (s.d.) DFS in LM and OM groups was 37.7 (5.9) and 33.4 (1.5) months, respectively. After propensity score-matched (PSM) analysis, 96 patients remained in OM group and 32 patients in LM group. In the PSM subset, patients in LM group still had comparable OS (P = 0.120) and DFS (P = 0.757) compared to patients in the OM group. After PSM, patients receiving LM had longer vascular exclusion time (P = 0.006) and shorter hospital stay (P = 0.004). In addition, LM was associated with reduced postoperative morbidity after PSM adjustment (P = 0.026). CONCLUSIONS: LM is associated with fewer complications and does not compromise survival compared with OM. LM can be recommended as a safe and reasonable surgical option in selected patients with CL-HCC.
BACKGROUND: Although laparoscopic mesohepatectomy (LM) has been performed for patients with centrally located hepatocellular carcinoma (CL-HCC), its short- and long-term benefits compared with traditional open surgery remain unclear. The aim of the present study was to explore the independent role of LM in the prognosis of patients with CL-HCC. METHODS: A retrospective analysis was undertaken of 348 patients who underwent mesohepatectomy for CL-HCC between January 2012 and October 2017 in our hospital. The impact of the surgical methods on long-term prognosis was evaluated by multivariable regression analysis. In addition, patients in the LM group were matched in a 1:3 ratio with open mesohepatectomy (OM) group. RESULTS: Some 307 patients underwent OM and 41 had LM. In both adjusted and non-adjusted models, patients in LM group had similar overall survival (OS, both P > 0.05) and disease-free survival (DFS, both P > 0.05) compared to OM patients. The mean (s.d.) OS in LM and OM groups was 41.6 (7.2) and 46.4 (1.4) months, respectively. The mean (s.d.) DFS in LM and OM groups was 37.7 (5.9) and 33.4 (1.5) months, respectively. After propensity score-matched (PSM) analysis, 96 patients remained in OM group and 32 patients in LM group. In the PSM subset, patients in LM group still had comparable OS (P = 0.120) and DFS (P = 0.757) compared to patients in the OM group. After PSM, patients receiving LM had longer vascular exclusion time (P = 0.006) and shorter hospital stay (P = 0.004). In addition, LM was associated with reduced postoperative morbidity after PSM adjustment (P = 0.026). CONCLUSIONS:LM is associated with fewer complications and does not compromise survival compared with OM. LM can be recommended as a safe and reasonable surgical option in selected patients with CL-HCC.
Authors: Go Wakabayashi; Daniel Cherqui; David A Geller; Joseph F Buell; Hironori Kaneko; Ho Seong Han; Horacio Asbun; Nicholas OʼRourke; Minoru Tanabe; Alan J Koffron; Allan Tsung; Olivier Soubrane; Marcel Autran Machado; Brice Gayet; Roberto I Troisi; Patrick Pessaux; Ronald M Van Dam; Olivier Scatton; Mohammad Abu Hilal; Giulio Belli; Choon Hyuck David Kwon; Bjørn Edwin; Gi Hong Choi; Luca Antonio Aldrighetti; Xiujun Cai; Sean Cleary; Kuo-Hsin Chen; Michael R Schön; Atsushi Sugioka; Chung-Ngai Tang; Paulo Herman; Juan Pekolj; Xiao-Ping Chen; Ibrahim Dagher; William Jarnagin; Masakazu Yamamoto; Russell Strong; Palepu Jagannath; Chung-Mau Lo; Pierre-Alain Clavien; Norihiro Kokudo; Jeffrey Barkun; Steven M Strasberg Journal: Ann Surg Date: 2015-04 Impact factor: 12.969
Authors: Kristian B Filion; Laurent Azoulay; Robert W Platt; Matthew Dahl; Colin R Dormuth; Kristin K Clemens; Nianping Hu; J Michael Paterson; Laura Targownik; Tanvir C Turin; Jacob A Udell; Pierre Ernst Journal: N Engl J Med Date: 2016-03-24 Impact factor: 91.245
Authors: Hyo Jun Kim; Jai Young Cho; Ho-Seong Han; Yoo-Seok Yoon; Hae Won Lee; Jun Suh Lee; Boram Lee; Yeongsoo Jo; Meeyouong Kang; Yeshong Park; Eunhye Lee Journal: Medicina (Kaunas) Date: 2022-05-30 Impact factor: 2.948
Authors: Ken Min Chin; Yun-Le Linn; Chin Kai Cheong; Ye-Xin Koh; Jin-Yao Teo; Alexander Y F Chung; Chung Yip Chan; Brian K P Goh Journal: J Gastrointest Surg Date: 2022-01-21 Impact factor: 3.452